Anti-diabetic and hypolipidemic effects of Sargassum yezoense in db/db mice
- 1 August 2012
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 424 (4), 675-680
- https://doi.org/10.1016/j.bbrc.2012.07.005
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Exploration of PPAR functions by microarray technology—A paradigm for nutrigenomicsBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2007
- Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitusDiabetologia, 2007
- International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated ReceptorsPharmacological Reviews, 2006
- The dual PPARα/γ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF ratsBritish Journal of Pharmacology, 2005
- Global Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030Diabetes Care, 2004
- Effect of thiazolidinediones on body weight in patients with diabetes mellitusAmerican Journal Of Medicine, 2003
- Minireview: Lipid Metabolism, Metabolic Diseases, and Peroxisome Proliferator-Activated ReceptorsEndocrinology, 2003
- Prevalence of Obesity, Diabetes, and Obesity-Related Health Risk Factors, 2001Published by American Medical Association (AMA) ,2003
- Obesity as a medical problemNature, 2000
- Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids.JCI Insight, 1997